Abiopharma

🔍 MAHON PAUL A (Executive)

Company: UNITED THERAPEUTICS Corp (UTHR)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Acquired 11,000 shares of Common Stock at $135.42 per share (Direct)
  Date: 2025-08-21 | Code: M | equity_swap_involved: false | shares_owned_after: 47,781.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 600 shares of Common Stock at $304.565 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 47,181.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 300 shares of Common Stock at $306.1233 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 46,881.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,441 shares of Common Stock at $307.3859 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 45,440.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,330 shares of Common Stock at $308.4281 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 43,110.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 4,234 shares of Common Stock at $309.4289 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 38,876.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 2,095 shares of Common Stock at $310.2485 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: false | shares_owned_after: 36,781.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 11,000 shares of Stock Option at $135.42 per share (Derivative)
  Date: 2025-08-21 | Code: M | Expires: 2027-03-15 | Exercise: 2023-03-15 | equity_swap_involved: false | shares_owned_after: 77,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024.
• F2: This transaction was executed in multiple trades at prices ranging from $305.63 to $306.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: This transaction was executed in multiple trades at prices ranging from $306.85 to $307.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: This transaction was executed in multiple trades at prices ranging from $307.85 to $308.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F5: This transaction was executed in multiple trades at prices ranging from $308.86 to $309.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F6: This transaction was executed in multiple trades at prices ranging from $309.86 to $310.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.